Contributions
Abstract: EP1444
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Comorbidity
Introduction: MD1003 is prescribed under a temporary authorization for use in progressive MS with good safety. More frequent comorbidities in this population may influence treatment results and should be taken into account.
Objectives: Identify side effects and comorbidities in a cohort of patients with progressive non-active form of MS treated with MD1003 for 12 months.
Methods: 109 patients (mean age 55 +/- 9.4 yrs, median EDSS 6.5, mean duration of illness 18.8 +/-9 yrs) with a progressive non-active form of MS worsening in the last 2 years have been followed for 12 months. Comorbidities likely to disturb the results of treatment evaluation are collected before introduction. At each visit (3, 6, 12 months) are noted sides effects and any undercurrent medical events related to the associated comorbidities or not. MRI results at baseline and at 12 months are also included.
Results: 55 patients have comorbidities: orthopaedic, metabolic and cardiorespiratory disorders. 15 patients discontinued treatment for inefficacy, adverse events and aggravation. 20 patients presented adverse events described in the characteristic summary produced. A sensorimotor relapse has been reported. One-third of patients suffered from an undercurrent medical event. Only one MRI showed an increase in the lesion load with two active lesions and two MRIs increased in isolated lesion load. Conclusion: Comorbidities are frequent according to the different publications and responsible for undercurrent events that may distort the therapeutic evaluation. Side effects are uncommon and comparable to those previously described. The risk of relapse remains low and corresponds to the risk described by Bonenfant in 2017 for progressive MS. MRI remains stable and may differ from other studies. MD1003 is a well-tolerated treatment and the evaluation of its effectiveness should take into account the more frequent associated comorbidities in this population.
Disclosure: nothing to disclose
Abstract: EP1444
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Comorbidity
Introduction: MD1003 is prescribed under a temporary authorization for use in progressive MS with good safety. More frequent comorbidities in this population may influence treatment results and should be taken into account.
Objectives: Identify side effects and comorbidities in a cohort of patients with progressive non-active form of MS treated with MD1003 for 12 months.
Methods: 109 patients (mean age 55 +/- 9.4 yrs, median EDSS 6.5, mean duration of illness 18.8 +/-9 yrs) with a progressive non-active form of MS worsening in the last 2 years have been followed for 12 months. Comorbidities likely to disturb the results of treatment evaluation are collected before introduction. At each visit (3, 6, 12 months) are noted sides effects and any undercurrent medical events related to the associated comorbidities or not. MRI results at baseline and at 12 months are also included.
Results: 55 patients have comorbidities: orthopaedic, metabolic and cardiorespiratory disorders. 15 patients discontinued treatment for inefficacy, adverse events and aggravation. 20 patients presented adverse events described in the characteristic summary produced. A sensorimotor relapse has been reported. One-third of patients suffered from an undercurrent medical event. Only one MRI showed an increase in the lesion load with two active lesions and two MRIs increased in isolated lesion load. Conclusion: Comorbidities are frequent according to the different publications and responsible for undercurrent events that may distort the therapeutic evaluation. Side effects are uncommon and comparable to those previously described. The risk of relapse remains low and corresponds to the risk described by Bonenfant in 2017 for progressive MS. MRI remains stable and may differ from other studies. MD1003 is a well-tolerated treatment and the evaluation of its effectiveness should take into account the more frequent associated comorbidities in this population.
Disclosure: nothing to disclose